Delta-8, Delta-9, and the Hemp Manufacturer's Compliance Documentation Problem

Delta-8 THC is legal under the 2018 Farm Bill. Delta-8 THC is banned in more than a dozen states. Delta-8 THC is being classified as a controlled substance by some federal agencies. Delta-8 THC is being defended as a lawful hemp derivative in federal courts.

All of these statements are currently true simultaneously, and if you're manufacturing delta-8 or any converted cannabinoid product, you already know how uncomfortable that ambiguity feels when a retailer asks a pointed question or a state law changes with sixty days' notice.

What you may not have considered is that the documentation you're keeping — or not keeping — is either your best protection or your biggest vulnerability when any of those legal questions get resolved against you.

This is not a legal opinion on whether delta-8 is lawful. That question has a different answer in every jurisdiction and changes frequently. This is a manufacturing documentation post about what you need to have on record if you're in this space, and why most manufacturers in the converted cannabinoid category are significantly underdocumented for the environment they're operating in.

Why the Converted Cannabinoid Category Has Unique Documentation Risk

Delta-8 THC does not exist in hemp flower in commercially meaningful concentrations. It is produced by chemically converting CBD — typically hemp-derived CBD isolate — through an acid-catalyzed isomerization process. The same process, with different conditions or different starting materials, can produce other converted cannabinoids: delta-10 THC, THC-O, HHC, THCP, and others that have emerged across the market.

This chemistry-based manufacturing process creates documentation risks that are different from standard botanical supplement manufacturing.

The starting material determines the legal status

The lawfulness of a delta-8 product under the Farm Bill depends on the starting material being hemp-derived — specifically, CBD isolate or distillate from hemp that was grown under a licensed hemp program and tested at or below 0.3% delta-9 THC at harvest.

If the starting material cannot be traced to a licensed hemp source with compliant testing documentation, the product's legal status under the Farm Bill is undermined regardless of the final product's cannabinoid profile. Your source documentation is not just good manufacturing practice — it is a component of the legal argument for your product's lawfulness.

The documentation you need: a receiving record for every lot of CBD isolate or distillate used in conversion, including the supplier's documentation of the licensed hemp source, the harvest COA confirming delta-9 THC compliance, and any chain of custody documentation between the farm and your facility.

The conversion process itself needs to be documented

The isomerization process that converts CBD to delta-8 involves acid catalysts, reaction conditions (temperature, time, concentration), and purification steps that affect the final product's purity and the presence of unwanted byproducts. Byproducts of delta-8 synthesis — including novel cannabinoids formed as reaction side products — have raised product safety questions that are unresolved in the literature.

Your batch records need to document the conversion process specifically: the reaction conditions used, the lot of starting material, the reagents used (including lot numbers and purity documentation for any acid catalyst), the purification steps, and the intermediate and final testing results. This documentation serves two purposes: quality assurance for your product, and evidence that your manufacturing process is controlled rather than variable.

Manufacturers who cannot document their conversion process cannot demonstrate that their product is consistent between batches, that it is free of process-related contaminants, or that the starting material was what it needed to be. These are the documentation gaps that regulators and prosecutors focus on when they pursue enforcement in this category.

Finished product testing for converted cannabinoids requires specificity

A standard cannabinoid potency panel tests for the most common cannabinoids and may not identify all converted cannabinoid byproducts at clinically relevant concentrations. Manufacturers of converted cannabinoid products need finished product testing that is specific to their product — including testing for the target cannabinoid at the labeled concentration and for the specific byproducts that their conversion process may generate.

The COA for a delta-8 product from a credible laboratory should include: delta-8 THC potency, delta-9 THC concentration (with a result at or below 0.3% to maintain Farm Bill compliance), a comprehensive cannabinoid panel, and testing for process-related impurities relevant to the specific synthesis method used.

Retailers who carry converted cannabinoid products — and there are fewer of them than there were three years ago — ask for this specificity in the COA. A general cannabinoid panel does not answer the questions they need answered.

The State Law Compliance Documentation Problem

Delta-8 is currently restricted or banned in Alaska, Arizona, Arkansas, Colorado, Delaware, Hawaii, Idaho, Iowa, Mississippi, Montana, Nevada, New York, North Dakota, Oregon, Rhode Island, Utah, Vermont, and Washington — a list that has grown steadily since 2021 and continues to change.

If you sell direct to consumers or through distribution in multiple states, your shipping documentation and order management records need to demonstrate that delta-8 products are not being shipped to restricted states. This is not just a business practice question — it is a documentation question. If a state regulatory agency investigates whether your products are being sold into their jurisdiction illegally, the records that demonstrate you have systems to prevent that are your defense.

What those records look like in practice: a documented compliance protocol for state law restrictions, logs showing that orders from restricted states are declined or redirected, and records of when your compliance list was last updated as state laws change.

This is documentation that most small and mid-size converted cannabinoid manufacturers have not formalized. The absence of it is not a problem until it becomes a problem — which in the current enforcement environment is a risk that deserves more weight than it typically gets.

What the DEA's Interim Rule Actually Said

In 2020, the DEA issued an Interim Final Rule that stated — in a footnote — that delta-8 THC produced through chemical synthesis is a Schedule I controlled substance, regardless of its hemp-derived starting material. The DEA's position is that the Farm Bill exempts hemp-derived cannabinoids that occur naturally in the plant, not those produced through synthetic chemical processes.

This interpretation has not been definitively upheld or rejected by federal courts, and the DEA has not aggressively enforced this position against manufacturers or retailers. But the position exists, it has been cited in state enforcement actions, and it is a legal risk that belongs in any honest assessment of where the converted cannabinoid category sits.

For manufacturers, the implication is not necessarily to stop producing delta-8 products — that is a business and legal decision that depends on your specific situation, jurisdiction, and legal counsel. The implication is that if the DEA's interpretation is eventually enforced, the manufacturers most likely to face consequences are those whose documentation does not demonstrate a good-faith effort to comply with the Farm Bill's requirements — specifically, those who cannot show that their starting material was lawfully produced hemp-derived CBD and that their conversion process was documented and controlled.

Building a Defensible Documentation Record for Converted Cannabinoids

Given the regulatory environment, the documentation standard for converted cannabinoid manufacturers should be higher than for standard hemp supplement manufacturers, not lower. The legal risk is greater. The regulatory attention is greater. The documentation that protects you needs to be correspondingly more complete.

The records that matter most:

1. Licensed hemp source documentation for all starting material. Every lot of CBD isolate or distillate used in conversion should have a receiving record that includes the supplier's licensed hemp source documentation and harvest COA. This is the evidentiary foundation for the Farm Bill compliance argument.

2. Conversion process batch records. For each production batch of converted cannabinoid, document the starting material lot, the reagents used, the reaction conditions, the purification steps, and the intermediate testing. This is not standard supplement manufacturing documentation — it is chemical manufacturing documentation. If your batch records don't capture this, they don't reflect what actually happened in your facility.

3. Finished product COAs with complete panels. Every finished product lot should have a COA from an ISO 17025 accredited laboratory that covers the target cannabinoid at labeled concentration, delta-9 THC at or below 0.3%, and testing for process-related impurities.

4. State compliance records. Documentation of your process for preventing sales into restricted jurisdictions, including logs of any orders declined or redirected based on destination state.

5. Chain of custody documentation. For converted cannabinoid products specifically, maintaining clear chain of custody from licensed hemp source through conversion through finished goods through distribution is the documentation that tells the story of how the product was made and from what. Gaps in that chain are gaps in the legal defense.

How Batch Buddy Supports Converted Cannabinoid Manufacturers

Batch Buddy's batch record and lot traceability system is designed for exactly the kind of multi-step, lot-sensitive manufacturing that converted cannabinoid production requires.

Lot-level receiving records with document attachment. Every incoming lot — CBD isolate, reagents, carrier materials — has a receiving record in Batch Buddy that captures supplier information, lot number, and attached documentation including COAs and source certificates. That documentation travels with the lot through every production step that uses it.

Multi-step batch records for conversion and formulation. Production runs in Batch Buddy capture actual quantities, lot numbers, and operator documentation for each step. For converted cannabinoid manufacturers, this means the conversion step and the formulation step are both documented, with traceability between them, in a single system.

Full chain traceability. A traceability search in Batch Buddy returns the complete chain from raw material lot to finished goods to shipment for any lot number. For a product under regulatory review, this is the document that tells the complete manufacturing story.

FDA 21 CFR Part 11 compliant audit trail. All records are logged with user identity, timestamp, and change history. Nothing is deletable. This is the documentation infrastructure that survives regulatory scrutiny — because it was built to withstand it.

Documentation Is Not a Substitute for Legal Advice

The converted cannabinoid space requires legal counsel that is current on federal enforcement positions and the specific laws in every state where your products are sold. This post is not that counsel. The documentation practices described here do not make an illegal product legal.

What documentation does is demonstrate that you operated in good faith, with controlled processes, from compliant source materials, with testing that supports your product claims. In a regulatory environment where the rules are contested and enforcement is unpredictable, that demonstration is meaningful. It does not eliminate risk. It meaningfully reduces it.

The manufacturers who have invested in compliant documentation practices are better positioned for every possible resolution of the current legal ambiguity — whether that's federal legalization with documentation requirements, enforcement against the category, or continuing grey-zone operation with increasing state-level scrutiny.

Build the records now. They are easier to build before you need them.

Batch Buddy supports hemp and CBD manufacturers with batch records, lot traceability, and COA management built to FDA 21 CFR Part 11 standards. Start your free 14-day trial.